Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination

Robust Antibody Levels in Both Diabetic and Non-Diabetic Individuals After BNT162b2 mRNA COVID-19 Vaccination

The emergence of effective vaccines for COVID-19 has been welcomed by the world with great optimism. Given their increased susceptibility to COVID-19, the question arises whether individuals with type-2 diabetes mellitus (T2DM) and other metabolic conditions can respond effectively to the mRNA-based...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Hamad Ali, Abdulmohsen Alterki, Sardar Sindhu, Barrak Alahmad, Maha Hammad, Salman Al-Sabah, Mohammad Alghounaim, Mohammad H. Jamal, Ali Aldei, Mohammad J. Mairza, Maitham Husain, Sriraman Deverajan, Rasheed Ahmad, Preethi Cherian, Irina Alkhairi, Abdullah Alkandari, Jehad Abubaker, Mohamed Abu-Farha, Fahd Al-Mulla
Formato: article
Lenguaje:EN
Publicado: Frontiers Media S.A. 2021
Materias:
COVID-19
diabetes mellitus type 2
vaccine
mRNA vaccine
BNT162b2
T2D
Immunologic diseases. Allergy
RC581-607
Acceso en línea:https://doaj.org/article/1e20e1ab130b4508b7d668fccca55432
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/1e20e1ab130b4508b7d668fccca55432

Ejemplares similares